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Autism Spectrum Disorder: the Early Markers for
Autism (EMA) study: a case-control study
Ousseny Zerbo1*, Cathleen Yoshida1, Judith K Grether1,2, Judy Van de Water3,4, Paul Ashwood4,5,
Gerald N Delorenze1, Robin L Hansen4,6, Marty Kharrazi2 and Lisa A Croen1Abstract
Background: Biologic markers of infection and inflammation have been associated with Autism Spectrum Disorders
(ASD) but prior studies have largely relied on specimens taken after clinical diagnosis. Research on potential biologic
markers early in neurodevelopment is required to evaluate possible causal pathways and screening profiles.
Objective: To investigate levels of cytokines and chemokines in newborn blood specimens as possible early biologic
markers for autism.
Methods: We conducted a population-based case-control study nested within the cohort of infants born from July
2000 to September 2001 to women who participated in the prenatal screening program in Orange County, California,
USA. The study population included children ascertained from the California Department of Developmental Services
with Autism Spectrum Disorder (ASD, n = 84), or developmental delay but not ASD (DD, n = 49), and general population
controls randomly sampled from the birth certificate files and frequency matched to ASD cases on sex, birth month
and birth year (GP, n = 159). Cytokine and chemokine concentrations were measured in archived neonatal blood
specimens collected for routine newborn screening.
Results: Cytokines were not detected in the vast majority of newborn samples regardless of case or control status.
However, the chemokine monocyte chemotactic protein-1 (MCP-1) was elevated and the chemokine Regulated upon
Activation Normal T-Cell Expressed and Secreted (RANTES) was decreased in ASD cases compared to GP controls. The
chemokines macrophage inflammatory protein-1alpha (MIP-1α) and RANTES were decreased in children with DD
compared to GP controls.
Conclusion: Measurement of immune system function in the first few days of life may aid in the early identification of
abnormal neurodevelopment and shed light on the biologic mechanisms underlying normal neurodevelopment.
Keywords: Newborn, Cytokines, Chemokines, Autism spectrum disordersBackground
Recent epidemiologic studies estimate that 1 to 2% of
children are affected by Autism Spectrum Disorder
(ASD) [1-3]. Although autism was first described in
1943 [4], very little is known about the etiology of the
vast majority of cases, and there are no definitive bio-
logical markers that clearly distinguish individuals with
ASD from unaffected individuals.* Correspondence: ousseny.x.zerbo@kp.org
1Division of Research, Kaiser Permanente Northern California, Oakland, CA
94612, USA
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unless otherwise stated.Several epidemiological studies have reported immune
dysregulation in children with ASD and their mothers,
suggesting a role for the immune system in the path-
ology of the disorder [5-9]. Several research groups have
found that individuals with ASD have increased neuroin-
flammation in brain tissues [10-12], imbalances in im-
munoglobulins, including increased levels of plasma
IgG4 [13], reduced levels of total IgG [14] or reduced
levels of IgG and IgM [15,16], and imbalances in cyto-
kine/chemokine levels [17,18]. However, the mechanisms
through which immune dysfunction may contribute to
the etiology of autism are not understood [19].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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regulating hematopoiesis, inflammation, and immune
cell proliferation and differentiation [20]. They also play
an important role in normal neurodevelopment, includ-
ing the processes of neuronal migration and synaptic
plasticity [21,22]. These processes are tightly regulated
and too much or too little of the signals mediated by cy-
tokines can be detrimental to the developing fetus. For
instance, in animal models, injection of the cytokine IL-
6 or IL-2 into pregnant mice leads to neurodevelopmen-
tal abnormalities in the offspring including decreased
prepulse inhibition and latent inhibition, attention, ex-
ploratory and social behaviors [23,24]. These findings
suggest that reported associations between maternal in-
fections or inflammation during pregnancy and ASD
[25-31] could be mediated through a disruption in the
balance of cytokine or chemokine levels.
The literature on cytokines/chemokines and ASD is
expanding; however, results are sometimes inconsistent
across studies [17,18,32-40]. The discrepancies are due
to different research groups having utilized different
types of bio-samples (serum, plasma, amniotic fluid),
different age groups, different types of control groups
(including siblings with likely inherited similarities with
respect to ASD), non-standardized blood draws from
differing seasons or times of day, and differences in
length of time between biosample collection and ASD
diagnosis (prenatal, newborn, post-ASD diagnosis). All
of these factors may contribute to variability across stud-
ies in measured concentration of cytokines/chemokines
and study findings [41] Among the reported results on
cytokines and chemokines in relation to autism, very few
studies have so far utilized newborn samples.
The objective of this new study was to examine the
potential association between cytokine and chemokine
profiles measured at birth and risk of Autism Spectrum
Disorders and developmental delays.
Methods
Study population
The study population has been previously described [42].
Briefly, the sample was derived from the Early Markers for
Autism (EMA) study, a population-based, nested case-
control study designed to evaluate biologic markers of
susceptibility and exposure in archived maternal mid-
pregnancy and neonatal blood specimens from the same
mother-baby pairs. The EMA population was drawn from
the cohort of children born in California from July 2000 to
September 2001 to women who were pregnant in Orange
County, California, USA, and who participated in the
State’s prenatal expanded alpha-fetoprotein screening pro-
gram (XAFP). Three groups of children were identified:
children with Autism Spectrum Disorder (ASD), children
with developmental delay (DD) but not ASD, and generalpopulation controls (GP). Children with ASD or DD were
ascertained from the California Department of Develop-
mental Services (DDS), which operates a system of 21
Regional Centers (RC) that coordinate services for persons
with ASD, mental disability, and other developmental dis-
abilities. GP controls were randomly sampled from the
birth certificate files after excluding all past or current
DDS/RC clients and were frequency matched to ASD
cases by sex, birth month and birth year at a 2:1 ratio.
Diagnostic verification
After initial ascertainment of children with ASD or DD
from records of the Regional Center of Orange County
(RCOC), medical record abstractors compiled detailed
diagnostic and clinical data from the RCOC records
following a protocol initially developed by the Metropol-
itan Atlanta Developmental Disabilities Surveillance Pro-
gram [43]. Expert clinical review of abstracted data was
then conducted by a developmental pediatrician (RLH)
to confirm the ASD or DD diagnoses for this study using
the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition (DSM-IV) criteria. The final analytic
sample consisted of 84 children with ASD, 49 children
with DD but not ASD, and 159 GP controls.
Specimen collection
Neonatal blood specimens were retrieved from the new-
born screening specimen archives maintained by the
California Department of Public Health. The neonatal spe-
cimen archive contains dried bloodspots collected for
screening purposes on nearly every infant born in California
(approximately 500,000 per year) since 1980. All newborn
blood specimens for children included in this study were
obtained by the heel-stick method, usually within 24 to 48
hours of birth. The blood specimens were collected at the
nursery on a special S&S filter paper, and allowed to dry at
room temperature prior to transport to the regional labora-
tory for routine screening for metabolic and other disor-
ders. During transport, usually by courier from the hospital
to a regional screening laboratory, the temperature of the
specimens was not controlled. Blood spots remaining after
routine testing were catalogued and stored at −20°C.
Cytokine and chemokine measurements
Neonatal cytokine and chemokine concentrations were
determined using a commercially available multiplex bead-
based kit (BioSource Human Bead Kit; Invitrogen,
Carlsbad, CA, USA). The following cytokines and chemo-
kines were measured: IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-1β,
IL-8, IL-10, IL-12p40, TNF-α, granulocyte macrophage
colony-stimulating factor (GM-CSF), IFN-γ-induced pro-
tein 10 (IP-10), monocyte chemotactic protein-1 (MCP-1),
macrophage inflammatory protein-1alpha and 1beta (MIP-
1α, MIP-1β), Regulated upon Activation Normal T-Cell
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kine 11 (CCL 11 or eotaxin). The assays were carried out
in accordance with the protocols provided by the manufac-
turer. Briefly, 50 μL of serum was incubated with anti-
cytokine-conjugated beads in a 96-well filter-bottomed
plate on a plate shaker. After two hours, the beads were
washed using a vacuum manifold, and biotin-conjugated
detection antibodies were added for one-hour incubation.
Following a repeat of the washing step, beads were incu-
bated with streptavidin phycoerythrin for 30 minutes. The
plates were then read on a Bio-Plex 100 system (Bio-Rad
Laboratories, Hercules, CA, USA) and analyzed using Bio-
Plex Manager Software (Bio-Rad Laboratories, Hercules,
CA, USA) with a five-point standard curve. Reference sam-
ples were run on each plate to determine assay consistency.
All laboratory assays were conducted blinded to case-
control status.
Statistical analysis
Socio-demographic factors were compared between ASD,
DD and GP groups using Chi-square test for categorical var-
iables and t-test for continuous variables. For all values of
analytes that were below the minimum detectable level
(MDL) we assigned a value of MDL/2. Concentration of
chemokines and cytokines were analyzed as untransformed,
since natural log transformation of the values did not sub-
stantially change their distribution. All analyses were cat-
egorical and cut-points were based on the percent of study
subjects with analyte values below the MDL. For analytes
with < 25% sample below the MDL, we divided the observa-
tions into quartiles based on the distribution among the GP
controls and used the lowest quartile as the reference.
Values below the MDL were included in the lowest quartile.
For analytes with 25 to 90% of the sample below the MDL,
we created a binary variable and compared detected versus
non-detected. Analytes with > 90% sample below the MDL
were not considered for further analysis.
To investigate whether analyte concentrations at the
extreme low or high end of the distribution predicted
case status, we included two additional cut-points com-
paring values below the tenth percentile versus above
the tenth percentile and values above the ninetieth per-
centile versus below the ninetieth, as was done in a pre-
vious study [32]. The 10th percentile cut-point was
introduced when < 5% of GP samples were below the
MDL. The 90th percentile cut-point was introduced
when < 25% of the GP samples were below the MDL We
conducted crude and adjusted analyses using logistic re-
gression to estimate the risk of ASD and DD associated
with each analyte separately. Covariates considered for
adjusted models were gender (male, female), child birth
month (calendar month), birth year (2000, 2001), mater-
nal ethnicity (Hispanic, non-Hispanic), maternal place of
birth (US, Mexico, other), maternal age at child birth(continuous in years), child age at blood draw (continu-
ous in days), gestational age (<37 weeks, ≥ 37 weeks).
Covariates were considered confounders and retained in
the final model if individually they changed the odds ra-
tio by 10% or more. Frequency matching variables (sex,
birth month, and birth year) were included in all logistic
regression models comparing ASD to GP control. Since
the specimens were spread out on different plates, we
additionally adjusted for laboratory plate as a categorical
variable. Odds ratios were estimated for exposure cat-
egories with a minimum cell count of 5.
The study was approved by the institutional review
boards of the California Health and Human Services
Agency and Kaiser Permanente of Northern California.
Results
There was no difference between ASD cases and GP con-
trols in gestational age, age at newborn screening, or birth
year. However, mothers of ASD cases were more likely to be
non-Hispanic, born in the US, and to be slightly older com-
pared to mothers of GP controls (Table 1). Children with
DD were more likely than GP controls to be male, have their
blood drawn slightly later and to be born in the year 2000
(Table 1).
For all cytokines and chemokines, the proportion of
newborn specimens with analyte levels below the MDL
was similar for children with ASD, children with DD, and
GP controls (Table 2). IL-5, IL-8, IL-12p40, TNF-α, IP-10,
MIP-1β and GM-CSF were not considered for further
analysis because they were detected in < 5% of specimens.
ASD versus GP controls
More than 50% of study subjects had levels of IFN-γ, IL-
1β, IL-2, IL-4, IL-6 and IL-10 below the MDL (Table 2).
ASD status was not associated with the detection of these
analytes in newborn bloodspots (Table 3). There was no
significant difference between ASD and GP groups in the
levels of MCP-1 when comparing quartiles in crude and
adjusted analysis. However, ASD cases were more likely
than GP controls to have levels of MCP-1 above the 90th
percentile (adjusted odds ratio (ORadj) = 3.24, 95% CI
1.41 to 7.47) (Table 3). We found no significant difference
in levels of MIP-1α between ASD cases and GP controls
when comparing quartiles or extreme values. For
RANTES, the proportion of ASD cases with concentra-
tion in the fourth quartile was lower than that of GP con-
trols (ORadj = 0.46, 95% CI 0.18 to 1.16). Moreover, a
significantly higher proportion of ASD cases had concen-
trations of RANTES at or below the 10th percentile com-
pared to GP controls (ORadj = 2.42, 95% CI 1.05 to 5.55)
(Table 3).
We found no significant association between levels of
eotaxin and risk of ASD compared to GP controls in
either crude or adjusted analyses (Table 3).
Table 1 Demographic characteristic of Autism Spectrum Disorder (ASD) cases, developmental delay (DD) and general
population (GP) controls - the Early Markers for Autism study
Characteristics ASD (n = 84) GP (n = 159) DD (n = 49) Chi-square
N (%) N (%) N (%) P-values
ASD versus GP DD versus GP
Gender
Male 73 (86.9) 139 (87.4) 29 (59.1) 0.89 < 0.01
Female 11 (13.1) 20 (12.6) 20 (40.8)
Maternal ethnicity
Hispanics 20 (23.8) 73 (45.9) 28 (57.1)
Non-Hispanics 64 (76.2) 86 (54.1) 21 (42.9) < 0.01 0.12
Maternal place of birth
US 45 (53.6) 71 (44.7) 16 (32.7) < 0.01 0.26
Mexico 9 (10.7) 58 (36.5) 22 (44.9)
Other 30 (35.7) 30 (18.8) 11 (22.4)
Maternal age (median and inter-quartile range) 31 (28 – 34) 28 (24 – 32) 29 (25 – 32) < 0.01 0.68
Gestational age (GA in days)
Preterm (GA < 260 days) 9 (10.7) 23 (14.5) 11 (22.5) 0.42 0.20
Term (GA≥ 260 days) 75 (89.3) 136 (85.5) 38 (77.5)
GA median and interquartile range 276 (269 – 280) 274 (267 – 279) 276 (265 – 282) 0.22 0.90
Child age (in days at newborn blood draw,
median and inter- quartile range)
1.22 (1.02 – 1.76) 1.18 (1.03 – 1.56) 1.40 (1.05 – 2.27) 0.38 0.03
Birth year
2000 23 (27.4) 31 (19.5) 26 (53) 0.15 < 0.01
2001 61 (72.6) 128 (80.5) 23 (47)
Table 2 Working range and proportion below the minimal detection level (MDL) for each analyte measured in
newborn dried blood by case-control status - the Early Markers for Autism study
Analytes Working range (pg/ml) ASD Cases (n =84) GP (n =159) DD (n = 49)
% below MDL % below MDL % below MDL
MCP-1 13.03 – 9,160 19.0 18.0 26.3
MIP-1α 6.1 – 28,800 0.0 1.2 4.1
RANTES 22.36 – 19,100 0.0 0.6 2.0
Eotaxin 1.37 – 9,200 19.0 9.0 14.3
IFN-γ 0.58 – 11,370 77.4 73.0 86.0
IL-1β 2.5 – 5,470 77.4 76.8 79.6
IL-2 1.45 – 9,530 67.9 69.2 83.7
IL-4 2.21 – 14,470 77.4 74.2 86.0
IL-6 1.88 – 12,360 77.4 74.8 79.6
IL-10 3.4 – 22,350 53.6 54.1 51.0
IL-5 1.75 – 11,490 100 100 100
IL-8 6.23 – 13,630 97.6 98.7 98.0
IL-12p40 2.74 – 6,000 100 99.4 100
TNF-α 3.96 – 8,660 100 99.4 100
IP-10 2.01 – 1,420 100 100 100
MIP-1β 5.3 – 10,370 96.4 94.3 98.0
GM-CSF 0.88 – 5,760 98.8 99.4 97.9
ASD: Autism Spectrum Disorder; DD: developmental delay; GP: general population; MDL: minimal detection level.
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Table 3 Crude and adjusted odds ratios with their 95% CIs Comparing levels of newborn blood spot cytokines/chemokines among children with Autism
Spectrum Disorder (ASD), developmental delays (DD) and general population controls (GP) - the Early Markers for Autism study
Exposure Exposure categories Developmental category ASD versus GP DD versus GP
ASD (N = 84) n (%) DD (N = 49) n (%) TD (N = 159) n (%) Crude OR (95% CI) Adjusted ORa ( 95% CI) Crude OR (95% CI) Adjusted ORb (95% CI)
MCP-1 Q1 27 (32.14) 17 (34.69) 41 (25.79) Reference Reference Reference Reference
Q2 13 (15.48) 14 (28.57) 39 (24.53) 0.50 (0.23 – 1.12) 0.49 (0.20 – 1.20) 0.86 (0.37 – 1.99) 0.52 (0.16 – 1.71)
Q3 15 (17.86) 9 (18.37) 39 (24.53) 0.58 (0.27 – 1.26) 0.48 (0.20 – 1.14) 0.55 (0.22 – 1.39) 0.45 (0.13 – 1.54)
Q4 29 (34.52) 9 (18.37) 40 (25.16) 1.10 (0.55 – 2.17) 0.93 (0.43 – 2.01) 0.54 (0.21 – 1.35) 0.55 (0.15 – 1.97)
≤ 90% 66 (78.57) 45 (91.84) 143 (89.94) Reference Reference Reference Reference
> 90% 18 (21.43) 4 (8.16) 16 (10.06) 2.43 (1.17 – 5.07) 3.24 (1.41 – 7.47) - -
MIP-1α Q1 23 (27.38) 22 (44.90) 41 (25.79) Reference Reference Reference Reference
Q2 20 (23.81) 7 (14.29) 39 (24.53) 0.91 (0.43 – 1.92) 0.86 (0.36 – 2.02) 0.33 (0.12 – 0.87) 0.21 (0.05 – 0.78)
Q3 19 (22.62) 13 (26.53) 42 (26.42) 0.80 (0.38 – 1.69) 1.01 (0.37 – 2.70) 0.57 (0.25 – 1.29) 0.36 (0.10 – 1.23)
Q4 22 (26.19) 7 (14.29) 37 (23.27) 1.06 (0.50 – 2.20) 1.53 (0.52 – 4.49) 0.35 (0.13 – 0.92) 0.29 (0.06 – 1.35)
>10% 70 (83.33) 14 (28.57) 143 (89.94) Reference Reference Reference Reference
≤ 10% 14 (16.67) 35 (71.43) 16 (10.06) 1.78 (0.82 – 3.86) 1.72 (0.71 – 4.14) 3.57 (1.59 – 8.01) 3.36 (1.16 – 9.69)c
≤ 90% 70 (83.33) 46 (93.88) 140 (88.05) Reference Reference Reference Reference
> 90% 14 (16.67) 3 (6.12) 19 (11.95) 1.47 (0.69 – 3.11) 1.76 (0.70 – 4.39) - -
RANTES Q1 26 (30.95) 21 (42.86) 40 (25.16) Reference Reference Reference Reference
Q2 23 (27.38) 9 (18.37) 40 (25.16) 0.88 (0.43 – 1.80) 0.82 (0.37 – 1.81) 0.42 (0.17 – 1.04) 0.34 (0.10 – 1.15)
Q3 20 (23.81) 14 (28.57) 40 (25.16) 0.76 (0.37 – 1.59) 0.63 (0.28 – 1.43) 0.66 (0.29 – 1.49) 0.55 (0.19 – 1.58)
Q4 15 (17.86) 5 (10.20) 39 (24.53) 0.59 (0.27 – 1.28) 0.46 (0.18 – 1.16) 0.24 (0.08 – 0.71) 0.14 (0.03 – 0.62)
> 10% 68 (80.95) 33 (67.35) 143 (89.94) Reference Reference Reference Reference
≤ 10% 16 (19.05) 16 (32.65) 16 (10.06) 2.10 (0.99 – 4.45) 2.42 (1.05 – 5.55) 4.33 (1.96 – 9.54) 3.78 (1.29 – 11.03)
≤ 90% 79 (94.05) 46 (93.88) 143 (89.94) Reference Reference Reference Reference
> 90% 5 (5.95) 3 (6.12) 16 (10.06) 0.56 (0.20 – 1.60) 0.59 (0.18 – 1.89) - -
Eotaxin Q1 25 (29.76) 17 (34.69) 41 (25.79) Reference Reference Reference Reference
Q2 23 (27.38) 9 (18.37) 37 (23.27) 1.02 (0.49 – 2.09) 0.95 (0.42 – 2.14) 0.58 (0.23 – 1.47) 0.88 (0.27 – 2.85)
Q3 19 (22.62) 12 (24.49) 42 (26.42) 0.74 (0.35 – 1.54) 0.58 (0.25 – 1.32) 0.68 (0.29 – 1.62) 0.62 (0.20 – 1.88)
Q4 17 (20.24) 11 (22.45) 39 (24.53) 0.71 (0.33 – 1.52) 0.60 (0.20 – 1.79) 0.68 (0.28 –1.63) 1.11 (0.27 – 4.58)
≤ 90% 76 (90.48) 44 (89.80) 143 (89.94) Reference Reference Reference Reference
> 90% 8 (9.52) 5 (10.20) 16 (10.06) 0.94 (0.38 – 2.29) 1.10 (0.36 – 3.34) 1.01 (0.35 – 2.93) 1.24 ( 0.34 – 4.42)c
IFN-γ Non-detected 65 (77.38) 42 (85.71) 116 (72.96) Reference Reference Reference Reference
Detected 19 (22.62) 7 (14.29) 43 (27.04) 0.78 (0.42 – 1.46) 0.91 (0.47 – 1.75) 0.45 (0.18 – 1.07) 0.64 (0.23 – 1.76)c
IL-1β Non-detected 65 (77.38) 39 (79.59) 122 (76.73) Reference Reference Reference Reference
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Table 3 Crude and adjusted odds ratios with their 95% CIs Comparing levels of newborn blood spot cytokines/chemokines among children with Autism
Spectrum Disorder (ASD), developmental delays (DD) and general population controls (GP) - the Early Markers for Autism study (Continued)
Detected 19 (22.62) 10 (20.41) 37 (23.27) 0.96 (0.51 – 1.80) 1.11(0.52 –2.35) 0.84 (0.38 – 1.85) 0.65 (0.19 – 2.23)
IL-2 Non-detected 57 (67.86) 41 (83.67) 110 (69.18) Reference Reference Reference Reference
Detected 27 (32.14) 8 (16.33) 49 (30.82) 1.06 (0.60 – 1.87) 1.14 (0.38 – 3.43) 0.43 (0.19 – 1.00) 0.26 (0.01 – 8.76)
IL-4 Non-detected 65 (77.38) 42 (85.71) 118 (74.21) Reference Reference Reference Reference
Detected 19 (22.62) 7 (14.29) 41 (25.79) 0.84 (0.45 – 1.56) 0.95 (0.49 – 1.85) 0.48 (0.20 – 1.15) 0.64 (0.23 – 1.80)c
IL-6 Non-detected 65 (77.38) 39 (79.59 119 (74.84) Reference Reference Reference
Detected 19 (22.62) 10 (20.41) 40 (25.16) 0.87 (0.46 – 1.62) 1.01 (0.52 – 1.96) 0.76 (0.34 – 1.66) 0.91 (0.35 – 2.35)c
IL-10 Non-detected 45 (53.57) 25 (51.02) 86 (54.09) Reference Reference Reference Reference
Detected 39 (46.43) 24 (48.98) 73 (45.91) 1.02 (0.60 – 1.73) 0.17 (0.02 – 1.55) 1.13 (0.59 – 2.14) 1.53 (0.68 – 3.48)c
aResults adjusted for maternal place of birth, child birth month, birth year, gender and specimen plate number.
bResults adjusted for maternal place of birth, child year of birth, gender, specimen plate number and child age at blood draw.
cResults adjusted for maternal place of birth, child year of birth, gender and child age at blood draw.
For MCP-1 and eotaxin, comparison between ≤ 10% versus > 10% was not possible because more than 5% of the sample was below MDL.
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A higher proportion of children with DD had concentra-
tions of MIP-1α and RANTES at or below the 10th percent-
ile compared to GP controls (for MIP-1α, ORadj = 3.36,
95% CI 1.16 to 9.69; for RANTES, ORadj = 3.78, 95% CI
1.29 to 11.03) (Table 3).
We found no significant association between levels of
MCP-1 or eotaxin and risk of DD compared to GP con-
trols in either crude or adjusted analyses (Table 3).Discussion
Children with ASD were more likely to have increased levels
of MCP-1 and decreased levels of RANTES in newborn
bloodspots compared to GP controls. Children with DD had
decreased levels of MIP-1α and RANTES compared to GP
controls.
Our finding of increased levels of MCP-1 in ASD
compared to GP controls contrasts with the study by
Abdallah and colleagues [32], who reported no case-
control differences in levels of MCP-1 measured in ar-
chived newborn blood samples from 359 ASD cases and
741 matched controls from Denmark. Our finding of no
difference in concentration of MIP-1α between ASD cases
and controls is similar to those previously reported by
Abdallah et al. (2012a). Like our study, they also found re-
duced levels of RANTES in ASD cases compared to con-
trols. However, in our study, this finding was not specific
to ASD cases, as we found that levels of RANTES were
also reduced in newborn blood specimens of children with
DD compared to GP controls.
In the present study, the vast majority of cytokines
were not detected in newborn blood specimens, and de-
tection was not associated with case-control status. Our
results are in contrast with those reported by Abdallah
et al. (2012) [35] who found decreased levels of IFN-γ,
IL-2, IL-4, and IL-6 and increased levels of IL-8 and sol-
uble IL-6 alpha (sIL-6rα) in newborn dried blood spots
from ASD cases and controls. Differences in laboratory
techniques, study populations, and length of time be-
tween sample collection and sample processing may
have led to the observed differences in results. In the
present study, samples were collected from children
born in 2000 and 2001 compared to the wide range in
year of birth of study participants of previous studies.
Alterations in chemokine and cytokine levels in other
specimen types have been previously reported. In an
analysis of chemokine levels in amniotic fluid Abdallah
et al. (2012) reported elevated levels of MCP-1 for chil-
dren who were later diagnosed with autism compared to
controls [34]. Whether the chemokines were of maternal
or fetal origin is not clear. Furthermore, increased levels
of MCP-1 in blood specimens collected from children
after the date of ASD diagnosis was reported in a studyof 2- to 5-year olds [17] that included 80 ASD cases and
37 typically developing controls.
MCP-1, RANTES and MIP-1α play a role in neuron
development. While often associated with inflammation,
sufficient levels of these chemokines are needed for
healthy neuronal migration. Therefore, changes in levels
during critical windows of development could alter neu-
rodevelopmental outcome leading to either ASD or DD,
as suggested by our data. Cytokines and chemokines
have overlapping biology and functions [44]. They are
known to be redundant and pleiotropic [45] which
makes the determination of the exact roles of specific
chemokines during neurodevelopment challenging [17].
Increased concentration of MCP-1 in ASD cases versus
controls may be suggestive of an increased immuno-
logical active state in newborns who are subsequently di-
agnosed with ASD.
The results of this study should be considered in light
of the following limitations. We were unable to validate
the diagnostic status of autism by systematic clinical
evaluation. Instead, we relied on expert review of infor-
mation recorded as part of diagnostic eligibility for de-
velopmental services from regional center records. In
addition, we did not have any clinical information such
as infection status of children at birth or their mothers.
Despite these limitations, the study was strengthened by
the measurement of a panel of chemokines and cyto-
kines in newborn blood samples, prior to when ASD or
DD diagnoses were made, so it gives us a window into
what was going on biologically during a critical period of
neurodevelopment. The inclusion of the DD group
allowed us to evaluate the specificity of the findings. We
were also able to adjust our results by including several
covariates in the multivariate analysis. Finally, our com-
parison group was matched to the ASD group.Conclusion
We found elevated levels of MCP-1 and decreased levels
of RANTES in the newborn blood of children subse-
quently diagnosed with ASD. Levels of RANTES and
MIP-1α were also decreased in children later diagnosed
with DD compared to GP controls. If replicated in future
studies, these findings suggest that measurement of im-
mune system function in the first few days of life may
aid in the early identification of particular neurodevelop-
mental trajectories. Further research on early biologic
markers will be useful in understanding the mechanisms
underlying early abnormal neurodevelopment.
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